TipRanks on MSN

Roche Exercises Option with Recursion Pharmaceuticals

An announcement from Recursion Pharmaceuticals ( ($RXRX) ) is now available. On October 29, 2025, Recursion Pharmaceuticals announced that Roche ...

Recursion Pharmaceuticals: Premium Valuation Without Proof (Rating Downgrade)

Recursion Pharmaceuticals shows high cash burn, limited efficacy data, and unproven platform validation. Check out why RXRX ...

Recursion to Report Third Quarter 2025 Business Updates and Financial Results on November 5th

Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will provide business updates and report its third quarter 2025 ...
Zacks Investment Research on MSN

Recursion Pharmaceuticals (RXRX) Stock Declines While Market Improves: Some Information for Investors

Recursion Pharmaceuticals (RXRX) closed at $5.91 in the latest trading session, marking a -6.19% move from the prior day. The stock fell short of the S&P 500, which registered a gain of 0.23% for the ...
eLife

A recursive pathway for isoleucine biosynthesis arises from enzyme promiscuity

The Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, Kongens Lyngby, Denmark ...